Skip to main content
Karl Illig, MD, Vascular Surgery, Tampa, FL

KarlArmisteadIlligMD

Vascular Surgery Tampa, FL

Physician

Are you Dr. Illig?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 91 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    2 Tampa General Cir
    Usf Vascular Surgery Ste.300
    Tampa, FL 33606
    Phone+1 813-259-0921
    Fax+1 813-259-0606

Summary

  • Dr. Karl Illig, MD is a vascular surgeon in Tampa, Florida. He is currently licensed to practice medicine in Florida, Texas, and South Carolina. He is affiliated with Surgery Specialty Hospitals of America.

Education & Training

  • University of Rochester
    University of RochesterFellowship, Vascular Surgery - Independent, 1995 - 1997
  • University of Rochester
    University of RochesterResidency, Surgery, 1988 - 1995
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 1988

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2021 - 2026
  • SC State Medical License
    SC State Medical License 2018 - 2023
  • FL State Medical License
    FL State Medical License 2011 - 2022
  • NY State Medical License
    NY State Medical License 1989 - 2018
  • American Board of Surgery Vascular Surgery

Awards, Honors, & Recognition

  • Top MD Consumers Checkbook
  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Arteriovenous Access Superficialization: A New Technique and Review of OptionsSeptember 2018
  • IP243. The Picture of a Vascular SurgeonMay 2018
  • IP107. Hemodynamic Events During Carotid Stenting Are Associated with Significant Periprocedural StrokeMay 2018

Press Mentions

  • Xeltis Announces FDA Breakthrough Device Designation for aXessTM and First Patient Treated in US Pivotal Trial
    Xeltis Announces FDA Breakthrough Device Designation for aXessTM and First Patient Treated in US Pivotal TrialNovember 14th, 2024
  • Are Athletes Getting More Injuries from TOS?
    Are Athletes Getting More Injuries from TOS?July 22nd, 2019
  • Blood Clots Have Become an Alarming Trend Among Hockey Players
    Blood Clots Have Become an Alarming Trend Among Hockey PlayersJanuary 13th, 2018
  • Join now to see all

Professional Memberships